Limits...
Reliable measurements of brain atrophy in individual patients with multiple sclerosis

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: As neurodegeneration is recognized as a major contributor to disability in multiple sclerosis (MS), brain atrophy quantification could have a high added value in clinical practice to assess treatment efficacy and disease progression, provided that it has a sufficiently low measurement error to draw meaningful conclusions for an individual patient.

Metrixmetrix: In this paper, we present an automated longitudinal method based on Jacobian integration for measuring whole‐brain and gray matter atrophy based on anatomical magnetic resonance images (MRI), named MS. MS is specifically designed to measure atrophy in patients with MS, by including iterative lesion segmentation and lesion filling based on FLAIR and T1‐weighted MRI scans.

Metrixmetrixmetrixmetrix: MS is compared with SIENA with respect to test–retest error and consistency, resulting in an average test–retest error on an MS data set of 0.13% (MS) and 0.17% (SIENA) and a consistency error of 0.07% (MS) and 0.05% (SIENA). On a healthy subject data set including physiological variability the test–retest is 0.19% (MS) and 0.31% (SIENA).

Metrix: Therefore, we can conclude that MS could be of added value in clinical practice for the follow‐up of treatment and disease progression in MS patients.

No MeSH data available.


Related in: MedlinePlus

Schematic overview of MSmetrix‐long. MSmetrix‐long starts with a quality control of the images. Subsequently, MSmetrix‐cross is performed for each time point. The results from the cross‐sectional step are used to initialize the longitudinal pipeline. In the longitudinal step, the brain atrophy is calculated based on a Jacobian integration in both directions
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036437&req=5

brb3518-fig-0001: Schematic overview of MSmetrix‐long. MSmetrix‐long starts with a quality control of the images. Subsequently, MSmetrix‐cross is performed for each time point. The results from the cross‐sectional step are used to initialize the longitudinal pipeline. In the longitudinal step, the brain atrophy is calculated based on a Jacobian integration in both directions

Mentions: The proposed method, for which an overview is shown in Fig. 1, starts with a 3D FLAIR and 3D T1‐weighted MR image for each of the time points. Each time point is processed independently by a cross‐sectional pipeline (MSmetrix ‐cross) that computes in a fully automated way segmentations of WM, GM, and CSF and produces T1‐weighted images that are bias corrected, lesion filled, and skull stripped. Subsequently, the longitudinal pipeline is executed.


Reliable measurements of brain atrophy in individual patients with multiple sclerosis
Schematic overview of MSmetrix‐long. MSmetrix‐long starts with a quality control of the images. Subsequently, MSmetrix‐cross is performed for each time point. The results from the cross‐sectional step are used to initialize the longitudinal pipeline. In the longitudinal step, the brain atrophy is calculated based on a Jacobian integration in both directions
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036437&req=5

brb3518-fig-0001: Schematic overview of MSmetrix‐long. MSmetrix‐long starts with a quality control of the images. Subsequently, MSmetrix‐cross is performed for each time point. The results from the cross‐sectional step are used to initialize the longitudinal pipeline. In the longitudinal step, the brain atrophy is calculated based on a Jacobian integration in both directions
Mentions: The proposed method, for which an overview is shown in Fig. 1, starts with a 3D FLAIR and 3D T1‐weighted MR image for each of the time points. Each time point is processed independently by a cross‐sectional pipeline (MSmetrix ‐cross) that computes in a fully automated way segmentations of WM, GM, and CSF and produces T1‐weighted images that are bias corrected, lesion filled, and skull stripped. Subsequently, the longitudinal pipeline is executed.

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: As neurodegeneration is recognized as a major contributor to disability in multiple sclerosis (MS), brain atrophy quantification could have a high added value in clinical practice to assess treatment efficacy and disease progression, provided that it has a sufficiently low measurement error to draw meaningful conclusions for an individual patient.

Metrixmetrix: In this paper, we present an automated longitudinal method based on Jacobian integration for measuring whole‐brain and gray matter atrophy based on anatomical magnetic resonance images (MRI), named MS. MS is specifically designed to measure atrophy in patients with MS, by including iterative lesion segmentation and lesion filling based on FLAIR and T1‐weighted MRI scans.

Metrixmetrixmetrixmetrix: MS is compared with SIENA with respect to test–retest error and consistency, resulting in an average test–retest error on an MS data set of 0.13% (MS) and 0.17% (SIENA) and a consistency error of 0.07% (MS) and 0.05% (SIENA). On a healthy subject data set including physiological variability the test–retest is 0.19% (MS) and 0.31% (SIENA).

Metrix: Therefore, we can conclude that MS could be of added value in clinical practice for the follow‐up of treatment and disease progression in MS patients.

No MeSH data available.


Related in: MedlinePlus